Last 162.50 GBp
Change Today 0.00 / 0.00%
Volume 159.0
INS On Other Exchanges
As of 11:35 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

instem plc (INS) Snapshot

162.50 GBp
Previous Close
162.50 GBp
Day High
162.50 GBp
Day Low
162.50 GBp
52 Week High
04/1/14 - 197.50 GBp
52 Week Low
01/8/14 - 139.50 GBp
Market Cap
Average Volume 10 Days
0.05 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for INSTEM PLC (INS)

Related News

No related news articles were found.

instem plc (INS) Related Businessweek News

No Related Businessweek News Found

instem plc (INS) Details

Instem Plc provides IT solutions to the early development healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include Provantis, a Windows-based system for organizations and universities engaged in non-clinical evaluation studies; ALPHADAS, an eSource, pro-active EDC system for early phase clinical trials; TRP, which provides toxicology solution for pharmaceutical, chemical, and contract research laboratory corporations; DISPENSE, a computer based system for test item control; Logbook, a solution to replace GLP and Non-GLP paper data; Submit, an integrated nonclinical solution suite; and SENDView, an application that simplifies the review of SEND datasets. The company also offers Animal Care Information System, a solution for managing animal facility; Centrus, a solution suite that provides early drug development information from various sources; Safety Intelligence Program, a Web-based database of toxicology and pathology intelligence; SRS, a data integration platform; Metawise, an ontology solution; and OmniViz, a data mining and visual analytics tool. In addition, it offers a range of services comprising project management, installation, validation, data management, training, solution development, remote systems, client support, and specialized solutions. Instem Plc has strategic partnerships with Microsoft; Oracle; CTCLS; Datapipe; SAS; Business Objects; and Asta Development. It serves pharmaceutical, chemical, and contract research organizations, including government and privately funded programs. The company was founded in 1969 and is headquartered in Stone, the United Kingdom.

130 Employees
Last Reported Date: 04/24/14
Founded in 1969

instem plc (INS) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 146.0K GBP
Chief Financial Officer, Secretary and Direct...
Total Annual Compensation: 94.0K GBP
Compensation as of Fiscal Year 2013.

instem plc (INS) Key Developments

Instem plc Wins Two Contract in Asia-Pacific

Instem plc announced that it has won two new contracts in the Asia-Pacific region. The first is a five-year contract with the National Shanghai Center for Drug Safety Evaluation and Research. Instem's Provantis solution will be delivered using the SaaS delivery model from Instem's Shanghai-based data center, adding another large and prestigious laboratory to Instem's established hosting data centre client roster. A second contract has been signed with an unnamed, leading Multi-national Corporation, which has purchased Instem's submit solution suite to support Clinical Data Interchange Standards Consortium's (CDISC) Standard for Exchange of Nonclinical Data (SEND).

NUVISAN Pharma Services Selects Instem's ALPHADAS to Accelerate Clinical Development Processes

Instem announced that NUVISAN Pharma Services has purchased the ALPHADAS(R) clinical trials software solution suite for deployment in its Phase I unit located in Neu-Ulm, Germany. Following a competitive evaluation of commercial software systems and vendors, NUVISAN selected Instem's ALPHADAS software suite based on its ability to support their clinical development team's specific needs through flexible configurations, the ability to integrate with other support systems through the unit and for Instem's rapid deployment services. In addition to improving processes at their Phase I unit, ALPHADAS will be integrating with NUVISAN's central lab operations resulting in enhanced quality and consistency while simultaneously improving efficiencies and saving time.

WIL Research Selects Instem plc as its Exclusive Non-Clinical Technology Partner

Instem plc announced that it has been selected by WIL Research as its exclusive non-clinical technology partner, to optimise study-related processes at all WIL worldwide sites. WIL Research has chosen Instem's entire Provantis software suite, including its Logbook ELN solution for paper form replacement, as part of a multi-year project. Instem's Toxicology Resource Planning solution is also a key element of the Provantis deployment, increasing efficiencies by enabling WIL Research to plan and manage studies and programs, allocate resources, benchmark against past studies and plan workloads for the future. WIL Research has additionally selected Instem's Centrus-submit™ solution to support SEND, the standardised reporting format for nonclinical data. The submit solution suite converts data from any source system into SEND files and allows sponsors, CROs and regulators such as the FDA to share, visualise and analyse study data more efficiently.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INS:LN 162.50 GBp 0.00

INS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INS.
View Industry Companies

Industry Analysis


Industry Average

Valuation INS Industry Range
Price/Earnings 35.6x
Price/Sales 1.7x
Price/Book 3.8x
Price/Cash Flow 17.0x
TEV/Sales 1.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSTEM PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at